|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/00 | |
| A61K 38/03 | |||
| A61K 38/04 | |||
| A61P 27/02 |
| (11) | Patento numeris | 2902035 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 14004427.2 |
| Europos patento paraiškos padavimo data | 2011-10-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-08-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-06-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| PCT/EP2010/0062 | 2010-10-14 | WO | |
| PCT/EP2011/0003 | 2011-01-25 | WO |
| (72) |
Combette, Jean-Marc, FR
Deloche, Catherine, CH
Abadie, Claire, FR
|
| (73) |
Xigen Inflammation Ltd.,
Arch. Makariou III 195 Neocleous House, 3030 Limassol,
CY
|
| (54) | Cell-permeable peptide inhibitors of the JNK signal transduction pathway for use in the treatment of inflammatory eye diseases. |
| Cell-permeable peptide inhibitors of the JNK signal transduction pathway for use in the treatment of inflammatory eye diseases. |